Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations

1

The COVID-19 pandemic significantly reduced hematopoietic stem cell transplantation (HSCT) activity for autoimmune diseases by 52% compared to 2019.
2

Multiple sclerosis and systemic sclerosis accounted for 80% of HSCT procedures for autoimmune diseases reported to the EBMT in 2020.
3

Guidelines for restarting HSCT programs emphasize careful patient evaluation and adherence to established treatment protocols.
4

Nurses play a crucial role in educating patients about infection precautions and the need for dedicated caregivers post-HSCT.
5

Individualized arrangements for HSCT patients are necessary, considering varying COVID-19 situations and guidelines across different regions.

Bone Marrow Transplantation

by Raffaella Greco, Tobias Alexander, Joachim Burman, Nicoletta Del Papa, Jeska de Vries-Bouwstra, Dominique Farge, Jörg Henes, Majid Kazmi, Kirill Kirgizov, Paolo A. Muraro, Elena Ricart, Montserrat Rovira, Riccardo Saccardi, Basil Sharrack, Emilian Snarski, Barbara Withers, Helen Jessop, Claudia Boglione, Ellen Kramer, Manuela Badoglio, Myriam Labopin, Kim Orchard, Selim Corbacioglu, Per Ljungman, Malgorzata Mikulska, Rafael De la Camara, John A. Snowden
May 24, 2021

1